Yi et al. (78) investigated the effects of this compound on the proliferation of breast cancer cell lines carrying different p53 status and found that YK-3-237 preferentially inhibited the proliferation of breast cancer cell lines carrying mutant p53. Here, TP53 is linked to breast cancer.